As retail investors flock to Viking Therapeutics, the biotech firm is also catching the eye of billionaire fund managers like ...

We recently published a list of 10 Worst Booming Stocks to Buy According to Short Sellers. In this article, we are going to ...

Three Motley Fool contributors think they've identified dirt-cheap healthcare stocks to buy right now. Here's why they picked CRISPR Therapeutics (NASDAQ: CRSP), Gilead Sciences (NASDAQ: GILD), and ...

Another biotech startup revealed plans Friday evening for an initial public offering, making it the sixth startup to list new ...

An office and lab property in Thousand Oaks has sold in an all-cash transaction. Los Angeles-based Alta West Partners and an ...

A rare-disease federal incentive program critical to biotech R&D is in jeopardy, writes Leslie Williams, president and CEO of ...

US-based financial services company Vanguard Group acquired shares worth Rs 998 crore in seven Indian companies via open market transactions on the NSE. Concurrently, Zurich-based UBS Group AG sold ...

A rather odd week in venture, as the biggest rounds were raised by greentech, business travel and charity startups. Of course ...

An early-stage biotech investor called YK Bioventures plans to raise $100 million, according to an SEC filing on Wednesday.

Slow enrollment in a key clinical trial has driven Genfit to rework the protocol to try to keep the study on track. | Slow ...

Ginkgo Bioworks is pivoting: Once a synthetic biology darling, the flailing company has now turned to AI-driven protein ...